Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about LDL: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
LDL is a concept in neurodegeneration research. Key relationships include: inhibits, activates, associated with. Associated with AD, ALI, ALS. Connected to 342 entities in the SciDEX knowledge graph.
No AI portrait yet
| Name | LDL |
| Key Genes/Proteins | ABCA1, ABCG1, ACACA, ACC, ACE, ACETYL-COA |
| Related Diseases | AD, Aging |
| Linked Hypotheses | 4 hypotheses |
Knowledge base pages for this entity
graph TD
LDL["LDL"]
LDL -->|"inhibits"| Atherosclerosis["Atherosclerosis"]
LDL -->|"activates"| ALS["ALS"]
LDL -->|"inhibits"| Inflammation["Inflammation"]
LDL -->|"inhibits"| Cardiovascular["Cardiovascular"]
LDL -->|"interacts"| AMPK["AMPK"]
LDL -->|"interacts"| ACTB["ACTB"]
LDLR["LDLR"] -->|"regulates"| LDL
ABCA1["ABCA1"] -->|"interacts"| LDL
MTOR["MTOR"] -->|"inhibits"| LDL
P62["P62"] -->|"interacts"| LDL
LC3["LC3"] -->|"interacts"| LDL
APOE["APOE"] -->|"inhibits"| LDL
SQSTM1["SQSTM1"] -->|"interacts"| LDL
GAIN["GAIN"] -->|"inhibits"| LDL
PCSK9["PCSK9"] -->|"inhibits"| LDL| Target | Relation | Type | Str |
|---|---|---|---|
| Atherosclerosis | inhibits | disease | 1.00 |
| APOE | inhibits | gene | 1.00 |
| Atherosclerosis | activates | disease | 1.00 |
| Als | inhibits | disease | 1.00 |
| Inflammation | activates | disease | 0.95 |
| Inflammation | inhibits | disease | 0.95 |
| oxidative stress response | participates_in | pathway | 0.90 |
| Cholesterol | associated_with | pathway | 0.90 |
| Cholesterol | inhibits | pathway | 0.90 |
| Lipid Metabolism | activates | pathway | 0.90 |
| Cholesterol | activates | pathway | 0.90 |
| Atherosclerosis | regulates | disease | 0.85 |
| Cardiovascular | regulates | disease | 0.85 |
| Cardiovascular | inhibits | disease | 0.85 |
| Aging | associated_with | disease | 0.85 |
| Myocardial Infarction | associated_with | disease | 0.85 |
| Als | associated_with | disease | 0.85 |
| ceramide | interacts_with | compound | 0.80 |
| macrophages | expressed_in | cell_type | 0.80 |
| Ceramide | transports | compound | 0.80 |
| unfolded protein response | participates_in | pathway | 0.80 |
| spinal muscular atrophy | associated_with | disease | 0.80 |
| GENES | associated_with | gene | 0.80 |
| APOE | associated_with | gene | 0.80 |
| Nf-Κb | inhibits | pathway | 0.80 |
| APOE | activates | gene | 0.80 |
| Atherosclerosis | associated_with | disease | 0.75 |
| Cardiovascular | associated_with | disease | 0.75 |
| Als | treats | disease | 0.75 |
| Fatty Liver | activates | disease | 0.75 |
| Tumor | inhibits | disease | 0.75 |
| Inflammation | treats | disease | 0.75 |
| Nafld | activates | disease | 0.75 |
| Stroke | associated_with | disease | 0.75 |
| Inflammation | associated_with | disease | 0.75 |
| Coronary Artery Disease | associated_with | disease | 0.75 |
| Fibrosis | inhibits | disease | 0.75 |
| Stroke | inhibits | disease | 0.75 |
| Cardiovascular | protects_against | disease | 0.75 |
| neural stem cells | activates | cell_type | 0.70 |
| autophagy pathway | participates_in | pathway | 0.70 |
| AMPK signaling | participates_in | pathway | 0.70 |
| SREBP2 | regulates | gene | 0.70 |
| Mtor | inhibits | pathway | 0.70 |
| Cholesterol | regulates | pathway | 0.70 |
| PCSK9 | regulates | gene | 0.70 |
| lipid metabolism | participates_in | pathway | 0.70 |
| AKT | inhibits | gene | 0.70 |
| Lipid Metabolism | regulates | pathway | 0.70 |
| MTOR | inhibits | gene | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| LDLR | regulates | protein | 0.97 |
| INFLAMMATION | activates | gene | 0.80 |
| PCSK9 | inhibits | gene | 0.70 |
| ABCA1 | activates | gene | 0.70 |
| INFLAMMATION | associated_with | gene | 0.70 |
| TNF-Α | inhibits | gene | 0.70 |
| LDLR | associated_with | gene | 0.70 |
| LDLR | activates | gene | 0.70 |
| PI3K | activates | gene | 0.70 |
| IL-6 | associated_with | gene | 0.70 |
| TNF | inhibits | gene | 0.70 |
| STROKE | associated_with | gene | 0.70 |
| statins | activates | compound | 0.70 |
| INFLAMMATION | inhibits | gene | 0.70 |
| NF-ΚB | inhibits | gene | 0.70 |
| APOE | interacts_with | gene | 0.65 |
| CD14 | associated_with | gene | 0.60 |
| PECAM1 | associated_with | gene | 0.60 |
| STROKE | treats | gene | 0.60 |
| CANCER | treats | gene | 0.60 |
| TNF | associated_with | gene | 0.60 |
| PI3K | regulates | gene | 0.60 |
| NF-ΚB | regulates | gene | 0.60 |
| VEGF | associated_with | gene | 0.60 |
| VCAM1 | associated_with | gene | 0.60 |
| TNF-Α | associated_with | gene | 0.60 |
| NEURODEGENERATIVE DISORDERS | interacts_with | gene | 0.60 |
| ALZHEIMER'S DISEASE | interacts_with | gene | 0.60 |
| AND | activates | gene | 0.60 |
| TAU | interacts_with | gene | 0.60 |
| NEURODEGENERATION | interacts_with | gene | 0.60 |
| NEURODEGENERATIVE DISEASES | interacts_with | gene | 0.60 |
| MITOCHONDRIAL DYSFUNCTION | interacts_with | gene | 0.60 |
| ALZHEIMER | interacts_with | gene | 0.60 |
| NEURON | interacts_with | gene | 0.60 |
| APOE4 | activates | gene | 0.60 |
| APOE3 | interacts_with | gene | 0.60 |
| SRC | activates | gene | 0.60 |
| AGING | activates | gene | 0.60 |
| GPR132 | activates | gene | 0.60 |
| AND | inhibits | gene | 0.60 |
| OLIGODENDROCYTE | inhibits | gene | 0.60 |
| ERK | interacts_with | gene | 0.60 |
| MIRNAS | inhibits | gene | 0.60 |
| MYELIN | activates | gene | 0.60 |
| VESICLE TRAFFICKING | contributes_to | gene | 0.60 |
| SREBF2 | contributes_to | gene | 0.60 |
| FASN | contributes_to | gene | 0.60 |
| SREBF1 | contributes_to | gene | 0.60 |
| CANCER | regulates | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| LDLR Ligand-Binding Domain A Fusion for Receptor-Mediated Tr | 0.650 | neurodegeneration | Blood-brain barrier antibody transport m |
| APOE4 preferentially signals through LRP1 over LDLR, alterin | 0.610 | neuroscience | APOE4-driven lipid metabolism dysregulat |
| oxLDL/LOX-1/ROS Signaling Induces P2RY12 via Nrf2 Activation | 0.550 | neurodegeneration | What determines P2RY12 receptor expressi |
| Poorly lipidated APOE4 particles are preferentially routed t | 0.340 | molecular biology | Does APOE4's reduced lipid-binding direc |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning LDL in their description or question text
No additional research found